ArticleProteomics2009
A proteomic-based approach for the identification of immunodominant Cryptococcus neoformans proteins.
Article in Proteomics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Caspofungin Affects Extracellular Vesicle Production and Cargo inJournal of fungi (Basel, Switzerland) · 2022Article
- Article
- Pathogen-Host Interaction Repertoire at Proteome and Posttranslational Modification Levels During Fungal Infections.Frontiers in cellular and infection microbiology · 2021Review
- Epitope-Based Immunoinformatic Approach on Heat Shock 70 kDa Protein Complex ofJournal of immunology research · 2021Article
- Identification of Disease-Associated Cryptococcal Proteins Reactive With Serum IgG From Cryptococcal Meningitis Patients.Frontiers in immunology · 2021Article
- Article
- IFN-γ immune priming of macrophages in vivo induces prolonged STAT1 binding and protection against Cryptococcus neoformans.PLoS pathogens · 2018Article
- A Call to Arms: Quest for a Cryptococcal Vaccine.Trends in microbiology · 2018Review
- Identification of T helper (Th)1- and Th2-associated antigens of Cryptococcus neoformans in a murine model of pulmonary infection.Scientific reports · 2018Article
- Protein Composition of Infectious Spores Reveals Novel Sexual Development and Germination Factors in Cryptococcus.PLoS genetics · 2015Article
- Cryptococcal heat shock protein 70 homolog Ssa1 contributes to pulmonary expansion of Cryptococcus neoformans during the afferent phase of the immune response by promoting macrophage M2 polarization.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Cryptococcus strains with different pathogenic potentials have diverse protein secretomes.Eukaryotic cell · 2015Article
- Absence of sodA Increases the Levels of Oxidation of Key Metabolic Determinants of Borrelia burgdorferi.PloS one · 2015Article
- Classical versus alternative macrophage activation: the Ying and the Yang in host defense against pulmonary fungal infections.Mucosal immunology · 2014Review
- Vaccine-mediated immune responses to experimental pulmonary Cryptococcus gattii infection in mice.PloS one · 2014Article
- Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responses.Proteomics · 2013Article
- Depletion of neutrophils in a protective model of pulmonary cryptococcosis results in increased IL-17A production by γδ T cells.BMC immunology · 2012Article
- Article
- Interleukin-17 is not required for classical macrophage activation in a pulmonary mouse model of Cryptococcus neoformans infection.Infection and immunity · 2010Article
- Pulmonary infection with an interferon-gamma-producing Cryptococcus neoformans strain results in classical macrophage activation and protection.The American journal of pathology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Cryptococcus neoformans is an opportunistic fungal pathogen that can cause life-threatening meningoencephalitis in immune compromised patients. Previous, studies in our laboratory have shown that prior exposure to an IFN-gamma-producing C. neoformans strain (H99gamma) elicits protective immunity against a second pulmonary C. neoformans challenge. Here, we characterized the antibody response produced in mice protected against experimental pulmonary C. neoformans infection compared to nonprotected mice. Moreover, we evaluated the efficacy of using serum antibody from protected mice to detect immunodominant C. neoformans proteins. Protected mice were shown to produce significantly more C. neoformans-specific antibodies following a second experimental pulmonary cryptococcal challenge compared to nonprotected mice. Immunoblot analysis of C. neoformans proteins resolved by 2-DE using serum from nonprotected mice failed to show any reactivity. In contrast, serum from protected mice was reactive with several cryptococcal protein spots. Analysis of these spots by capillary HPLC-ESI-MS/MS identified several cryptococcal proteins shown to be associated with the pathogenesis of cryptococcosis. Our studies demonstrate that mice immunized with C. neoformans strain H99gamma produce antibodies that are immune reactive against specific cryptococcal proteins that may provide a basis for the development of immune based therapies that induce protective anticryptococcal immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.